Mid-Valley Gastroenterology - Corvallis

Mid-Valley Gastroenterology - Corvallis · 3521 Northwest Samaritan Drive · Corvallis, OR 97330

4.8· 603 Google reviews

Listing updated October 2, 2026

Retatrutide outlook for this practice

No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.

About this practice

The official website for Mid-Valley Gastroenterology - Corvallis in Corvallis, OR did not load (ConnectionError: HTTPConnectionPool(host='www.midvalleygi.com', port=80): Max retries exceeded with url: / (Caused by NameResolutionError("<urllib3.connection.HTTPConnection object at 0x7f263c3347c0>: Failed to resolve 'www.midvalleygi.com' ([Errno -2] Name or service not known)"))), so this summary cannot be grounded in first-party page content. No medications, prices, or services are inferred from the directory dump.

Services & access

Advertises semaglutide today	Not listed
Advertises tirzepatide today	Not listed
Telehealth visits	Not listed
Cash pay accepted	—
Accepts insurance — per practice website	Yes
Accepting new patients — per practice website	Yes

"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.

Retatrutide status

Phase 3 complete · Not FDA-approvedUpdated October 2, 2026

Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.

Development: Phase 3 complete
FDA status: Submission planned — Q1 2027 (Lilly guidance)
Availability: Not commercially available
Access routes: Clinical trials, or Lilly's expanded access program (physician must apply)

Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)

Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs